Add Presentation to Slide Tray Presentation:
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Evaluating JIA Assessment Instruments (1 of 3)
For this review, seven individual outcomes instruments that are used in composite assessments were evaluated. They measure:
- Disease activity, using Active Joint Count (AJC), physician global assessment of disease activity (PGA), or parent global assessment of well-being (PGW)
- Functional status and disability, using the Childhood Health Assessment Questionnaire (CHAQ)
- Health-related quality of life, using the Child Health Questionnaire (CHQ), the Pediatric Quality of Life Inventory (PedsQL), and the Pediatric Quality of Life Inventory–Rheumatology Module (PedsQL-RM)
Keywords: active joint count | anti-rheumatic | antirheumatic | assessment | biologic DMARD | CHAQ | CHQ | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent global assessment of well-being | PedsQL | PedsQL-RM | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.